Kara Eastman, the Democratic nominee in Nebraska’s Second Congressional District, tells a story while campaigning about visiting her mother while she was dying from cancer. Her mother’s medicals bills were stacked so high on the kitchen table, Eastman says, that when she visited, they couldn’t see each other through the piles. Just one of her mother’s pills cost $2,500 a month.
Eastman decided to run for Congress to offer alternatives to the skyrocketing cost of health care. She campaigns calling for Medicare for All and further solutions to the crisis of unaffordable prescription drugs. Her message is resonating. She beat a well-known opponent in her primary by a few hundred votes.
Spending on prescription drugs is growing faster than any other sector of our health-care system. Drug companies, meanwhile, are raking in record profits, far higher than those in other industries—and they are spending considerably more of it on buybacks and dividends than on research and development. Most importantly for their bottom line, they are breaking records with their spending to influence CongressFull artivle: to protect their monopolies.
Drug company revenues soared from $534 billion in 2006 to $775 billion in 2015. That’s billion with a “b.”
Full article: https://goo.gl/NAciCQ